



Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Diversity-oriented synthesis of 1,3-benzodiazepines

Gaigai Wang^{a,1}, Chao Liu^{a,1}, Binbin Li^a, Yingchun Wang^a, Kristof Van Hecke^b, Erik V. Van der Eycken^{c,d}, Olga P. Pereshivko^{a,**}, Vsevolod A. Peshkov^{a,*}

^a College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Dushu Lake Campus, Suzhou, 215123, China

^b XStruct, Department of Inorganic and Physical Chemistry, Ghent University, Krijgslaan 281-S3, B-9000, Ghent, Belgium

^c Laboratory for Organic & Microwave-Assisted Chemistry (LOMAC), Department of Chemistry, University of Leuven (KU Leuven), Celestijnenlaan 200F, 3001, Leuven, Belgium

^d Peoples Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya Street, Moscow, 117198, Russia

ARTICLE INFO

Article history:

Received 26 June 2017

Received in revised form

13 September 2017

Accepted 18 September 2017

Available online xxx

Keywords:

A³-coupling

Propargylamines

Isocyanates

Reductive Heck reaction

1,3-Benzodiazepines

Medium-rings

ABSTRACT

A concise assembly of the 1,3-benzodiazepine core from A³-coupling-derived propargylamines and *ortho*-bromophenylisocyanates is described. The developed synthetic sequence involves the addition of propargylamine to isocyanate followed by palladium-catalyzed intramolecular alkyne hydroarylation that could be accomplished in a stepwise or one-pot manner.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Nitrogen-containing seven-membered heterocyclic systems such as 3-benzazepine¹ and 1,4-benzodiazepine² constitute a core structural elements of many natural and biologically active molecules and therefore could be rightfully designated as privileged structures (Fig. 1).³ Fenoldopam, a representative 3-benzazepine-containing medication, is the first selective peripheral dopamine receptor agonist approved for clinical use for the treatment of severe hypertension.⁴ Diazepam belongs to a large family of 1,4-benzodiazepine-based psychoactive drugs whose mechanism of action involves the enhancement of the inhibitory activity of the gamma-aminobutyric acid (GABA) neurotransmitter at the GABA_A receptor, resulting in sedative, sleep-inducing, anxiolytic, alcohol withdrawal, anticonvulsant, and muscle relaxant therapeutic properties.⁵

1,3-Benzodiazepine skeleton, which results from a small structural deviation from the above scaffolds (Fig. 1), has been relatively less studied in terms of synthesis⁶ and potential biological and therapeutic applications.⁷ Therefore, we set a goal to develop a combinatorial route to provide a diversity-oriented entry to this medium-ring-containing class of heterocycles.

Recently, others and we made substantial efforts on exploiting A³-coupling-derived propargylamines in heterocyclic chemistry.^{8,9} Subjecting secondary propargylamines **1** to a palladium-catalyzed intramolecular alkyne hydroarylation process, we were able to attain a small set of 3-benzazepines **2** (Scheme 1).^{10,11} Using primary propargylamines **3**, we have developed a series of protocols that selectively convert *in situ* generated propargylureas **4** into imidazol-2-ones **5**,^{12,13} imidazolidin-2-ones **6**,¹⁴ oxazolidin-2-imines **7**,¹⁵ and pyrimidin-2-ones **8**¹⁶ via silver- or gold-catalyzed cycloisomerizations (Scheme 1).

2. Results and discussion

Inspired by these processes, we envisaged that the 1,3-benzodiazepine core **9** could be assembled by a palladium-catalyzed intramolecular alkyne hydroarylation of propargylic

* Corresponding author.

** Corresponding author.

E-mail addresses: olga@suda.edu.cn (O.P. Pereshivko), vsevolod@suda.edu.cn (V.A. Peshkov).

¹ These authors contributed equally to this work.





Fig. 1. Nitrogen-containing seven-membered heterocyclic systems.


ureas **10** derived from secondary propargylamines **3** and *ortho*-bromophenyl isocyanates **11** (Scheme 2). The proposed hydroarylation process involves an oxidative insertion of the Pd(0)-catalyst into the arylbromide moiety of **10**, followed by a triple

bond carbopalladation and subsequent trapping of the resulting vinyl-palladium species **A** with sodium formate as reducing agent. The carbopalladation step is crucial for the whole process and allows to control the ring size and the double bond geometry in the forming 1,3-benzodiazepine product **9** (Scheme 2).¹⁷ The required secondary propargylamines **3** are readily accessible from primary amines **12**, aldehydes **13** and terminal acetylenes **14** through a CuBr-catalyzed A³-coupling protocol (Scheme 2).¹⁸


Reacting propargylamine **3a** with *ortho*-bromophenyl isocyanate (**11a**) gave propargylurea **10a** in 98% yield. In turn, this substrate was selected to perform the optimization of the Pd-catalyzed intramolecular alkyne hydroarylation that is also frequently referred to as reductive Heck reaction (Table 1). Conducting this transformation in DMF/H₂O mixtures that previously proved to be beneficial for such processes delivered desired 1,3-benzodiazepine **9a** albeit in low yield of maximum 38% (Table 1, entries 1–3). At the same time, this was accompanied by the degradation of significant amounts of urea **10a** back to the propargylamine **3a** (Table 1, entries 1–3). Using DMF or *i*PrOH as solvent gave no or little of **3a**, but the yield of target **9a** remained insufficient (Table 1, entries 4–6), despite some enhancement observed when reaction in DMF was conducted in the presence of phase-transfer catalyst (Table 1, entry 5). To our delight, the yield of **9a** was substantially improved by



Scheme 1. Synthesis of various heterocycles from the A³-coupling-derived propargylamines **1** and **3**.



Scheme 2. Strategy towards 1,3-benzodiazepines **9**.

Table 1Optimization of the Pd-catalyzed intramolecular alkyne hydroarylation (reductive Heck) step.^a


Entry	Catalyst	Solvent	Time, h	Yield, % ^b	
				9a	3a
1	Pd(PPh ₃) ₄	DMF/H ₂ O (3:1)	1	13	43
2	Pd(PPh ₃) ₂ Cl ₂	DMF/H ₂ O (3:1)	1	38	15
3	Pd(PPh ₃) ₂ Cl ₂	DMF/H ₂ O (9:1)	1	21	25
4	Pd(PPh ₃) ₂ Cl ₂	DMF	1	36	—
5 ^c	Pd(PPh ₃) ₂ Cl ₂	DMF	2	46	—
6	Pd(PPh ₃) ₂ Cl ₂	<i>i</i> PrOH	4	34	9
7	Pd(PPh ₃) ₂ Cl ₂	<i>i</i> PrOH/H ₂ O (3:1)	4	62	26
8	Pd(PPh ₃) ₂ Cl ₂	<i>i</i> PrOH/H ₂ O (4:1)	4	57	14
9	Pd(PPh ₃) ₂ Cl ₂	<i>t</i> BuOH/H ₂ O (3:1)	4	55	18
10	3 mol% Pd(OAc) ₂ /6 mol% PPh ₃	<i>i</i> PrOH/H ₂ O (3:1)	4	54	15
11	Pd(PPh ₃) ₄	<i>i</i> PrOH/H ₂ O (3:1)	4	28	38
12 ^d	10 mol% Ni(cod) ₂ /20 mol% P(<i>n</i> Bu) ₃	THF	18	— ^e	—

^a The reactions were run at 110 °C on 0.25 mmol scale in 2 mL of solvent with 1.5 equiv of sodium formate as reducing agent.^b The yields of **9a** and **3a** were determined by ¹H NMR of the reaction mixture after work-up using 3,4,5-trimethoxybenzaldehyde as internal standard.^c The reaction was conducted in the presence of 1 equiv of tetra-butylammonium bromide (TBAB).^d The reaction was conducted at 100 °C in 0.5 mL of THF with 1.2 equiv of triethylsilane as reducing agent.^e 65% of unreacted **10a** was detected by ¹H NMR analysis of reaction mixture after removal of nickel catalyst by filtration through a short plug of silica gel. cod = 1,5-cyclooctadiene.

switching to *i*PrOH/H₂O or *t*BuOH/H₂O mixtures as the reaction media, although the competing degradation of **10a** into **3a** could not be completely suppressed (Table 1, entries 7–9). The best result was obtained for the reaction with Pd(PPh₃)₂Cl₂ as a catalyst and *i*PrOH/H₂O (3:1) as solvent producing **9a** in 62% yield as was determined by ¹H NMR analysis of reaction mixture (Table 1, entry 7). Pd(OAc)₂/PPh₃ and Pd(PPh₃)₄ showed lower efficiency under the same settings (Table 1, entries 10 and 11) while an attempt to utilize

one of the literature protocols based on nickel catalysis¹⁹ was completely unproductive (Table 1, entry 12).

Having effective conditions for the Pd-catalyzed alkyne hydroarylation step in hands, we moved to exploring the scope and limitations of our strategy (Scheme 3). The required propargylurea precursors **10** were obtained in high yields by reaction of propargylamines **3** with *ortho*-bromophenyl isocyanates **11**. The high efficiency of this transformation motivated us to compare the

**Scheme 3.** Scope of the Pd-catalyzed intramolecular alkyne hydroarylation leading to 1,3-benzodiazepine **9**.




Fig. 2. X-ray crystallographic molecular structure of 1,3-benzodiazepine **9d**, showing thermal displacement ellipsoids at the 50% probability level.

sequential and one-pot approaches, when combining it with the final Pd-catalyzed alkyne hydroarylation process (Scheme 3). Using propargylureas **10a–j** bearing a (hetero)aromatic substituent on the triple-bond and with no additional substituents on the isocyanate-derived benzene ring ($R^4 = \text{H}$), the target 1,3-benzodiazepines **9a–j** were obtained in up to 62% and 52% for the stepwise and one-pot approaches, respectively. The structure of the representative 1,3-benzodiazepine **9d** was confirmed by X-ray crystallographic analysis (Fig. 2).²⁰ Conducting the Pd-catalyzed intramolecular alkyne hydroarylation with substrates **10k,l** bearing alkyl group on the triple-bond, led to an unclear reaction hampering the isolation of desired products **9k,l**. Thus, 1,3-benzodiazepines **9k,l** were obtained in a lower purity. The reactions of propargylureas **10m,n** derived from branched isocyanate **11b** ($R^4 = 4,6\text{-diMe}$) delivered 1,3-benzodiazepines **9m,n** in 64% and 69%, respectively (stepwise approach).

With not too many *ortho*-bromophenyl isocyanates **11** being commercially available, we turned our attention to the corresponding *ortho*-bromophenyl carboxylic acids **15a,b**. Reacting later with diphenylphosphoryl azide (DPPA) in the presence of triethylamine gave rise to the desired isocyanates **11c,d** through a Curtius rearrangement of initially formed acyl azides **16a,b**.²¹ The reaction mixtures containing either **11c** or **11d** were directly treated with propargylamine **3c** allowing to attain propargylurea precursors **10o,p**. Finally, Pd-catalyzed cyclization afforded 1,3-benzodiazepines **9o,p** featuring electron donating or electron withdrawing R^4 substituents (Scheme 4).

It is important to stress, that despite the moderate efficiency in the Pd-catalyzed alkyne hydroarylation step, the overall synthetic sequence towards 1,3-benzodiazepines **9** starting from amines **12**, aldehydes **13** and acetylenes **14** proved to be operationally simple and robust. In fact, we have developed and implemented a practical exercise for the fourth year undergraduate students, which is based

on this three-step methodology. The results obtained during 2016/2017 academic year at Soochow University, China demonstrate that the students from the intensive training class could satisfactorily reproduce the procedures described in this study with a minimal failure rate.²²

In order to further extend the scope of our strategy and to introduce an additional diversity point into target 1,3-benzodiazepine scaffold, we evaluated a base-promoted N-alkylation reaction of **9** (Scheme 5a). Reacting 1,3-benzodiazepines **9** with benzyl chlorides **17** or with methyl iodide (**18**) in the presence of sodium hydride smoothly produced alkylated 1,3-benzodiazepines **19** in up to 96%. Another viable synthetic manipulation involved an acid-promoted removal of the *para*-methoxybenzyl group²³ from the substrate **9f** to afford 1,3-benzodiazepine **20** containing two unprotected NH groups (Scheme 5b left). Interestingly, an analogous transformation of **9e** bearing phenyl group at the allylic position was accompanied by a double-bond migration leading to the formation of isomerized 1,3-benzodiazepine **21** (Scheme 5b right).

3. Conclusion

In summary, we have developed a diversity-oriented strategy towards 1,3-benzodiazepines that involves a one-pot or sequential reaction of A^3 -coupling-derived propargylamines with *ortho*-bromophenylisocyanates, followed by a palladium-catalyzed intramolecular alkyne hydroarylation. An additional N-alkylation step further enriches the overall strategy allowing to construct a 1,3-benzodiazepine core featuring five points of diversity.


4. Experimental

4.1. General information


All starting materials and solvents were purchased from commercial sources and used as received. Melting points were measured using INESA WRR apparatus. Infrared (FT-IR) spectra were recorded neat on a Bruker Vertex 70. ^1H (400 MHz) and ^{13}C (100 MHz) NMR spectra were recorded using a Bruker Avance III HD instrument. The ^1H and ^{13}C chemical shifts are reported relative to TMS using the residual CDCl_3 signal as internal reference. HRMS were performed on a Bruker micrOTF-Q III.

4.2. General procedure for the synthesis of secondary propargylamines **3**

Copper (I) bromide catalyst (17 mg, 0.12 mmol) was placed in a screw cap vial followed by addition of dry toluene (1.0 mL), amine **12** (0.8 mmol), aldehyde **13** (1 mmol), and phenyl acetylene **14** (1.6 mmol). The resulting mixture was flushed with argon, sealed and stirred at 100 °C for 5 h. Upon completion of this time, the mixture was diluted with ethyl acetate and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on



Scheme 4. Extended scope of the Pd-catalyzed intramolecular alkyne hydroarylation leading to 1,3-benzodiazepine **9**.

Scheme 5. Base-promoted alkylation of **9** and PMB-deprotection of **9f** and **9e**.

silica gel using petroleum ether-ethyl acetate (9:1 $\rightarrow$ 8:2) mixture as eluent provided pure propargylamine **3**.

4.3. General procedure for the synthesis of propargylureas **10a–n**

Propargylamine **3** (0.7 mmol) was placed in a screw cap vial followed by addition of dry DCM (2.8 mL) and *ortho*-bromophenyl isocyanate **11** (1.05 mmol). The resulting mixture was sealed and stirred at rt for 0.5 h. Upon completion of this time, the mixture was diluted with ethyl acetate and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on silica gel using petroleum ether-ethyl acetate (49:1 $\rightarrow$ 9:1) mixture as eluent provided pure propargylurea **10**.

4.4. General procedure for the synthesis of propargylureas **10o,p**^{21c}

2-Bromobenzoic acid **15** (2.5 mmol) was placed in a screw cap vial followed by addition of dry dioxane (6 mL), diphenylphosphoryl azide (DPPA, 688 mg, 2.5 mmol) and triethylamine (273 mg, 2.7 mmol). The resulting mixture was sealed and stirred at rt for 1 h followed by heating at 100 °C for another 2 h. Then propargylamine **3c** (459 mg, 2 mmol) in dry dioxane (4 mL) was added and the mixture was continued to stir at rt for 1 h. Upon completion of this time, the mixture was diluted with ethyl acetate and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on silica gel using petroleum ether-ethyl acetate (9:1 for **10o**; 47:3 for **10p**) mixture as eluent provided pure propargylurea **10**.

4.5. General procedure for the synthesis of 1,3-benzodiazepines **9** through the Pd-catalyzed intramolecular alkyne hydroarylation

Propargylurea **10** (0.5 mmol), bis(triphenylphosphine)palladium(II) dichloride (10.5 mg, 0.015 mmol) and sodium formate (51 mg, 0.75 mmol) were placed in the screw cap vial followed by addition of isopropanol (3 mL) and water (1 mL). The resulting mixture was flushed with argon, sealed and stirred at 100 °C for 4 h. Upon completion of this time, the mixture was diluted with ethyl acetate

and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on silica gel using petroleum ether-ethyl acetate (9:1 $\rightarrow$ 8:2 $\rightarrow$ 1:1) mixture as eluent provided 1,3-benzodiazepine **9**.

4.6. General procedure for the one-pot synthesis of 1,3-benzodiazepines **9**

Propargylamine **3** (0.5 mmol) was placed in a screw cap vial followed by addition of dry DCM (2 mL) and *ortho*-bromophenyl isocyanate **11** (0.75 mmol). The resulting mixture was sealed and stirred at rt for 0.5 h. Upon completion of this time, the vial was open and the DCM was evaporated under the ambient condition. The crude propargylurea **10** was transferred to the next step. Bis(triphenylphosphine)palladium(II) dichloride (10.5 mg, 0.015 mmol) and sodium formate (51 mg, 0.75 mmol) were added to the vial with the crude urea **10** followed by addition of isopropanol (3 mL) and water (1 mL). The resulting mixture was flushed with argon, sealed and stirred at 100 °C for 4 h. Upon completion of this time, the mixture was diluted with ethyl acetate and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on silica gel using petroleum ether-ethyl acetate (9:1 $\rightarrow$ 8:2 $\rightarrow$ 1:1) mixture as eluent provided 1,3-benzodiazepine **9**.

4.6.1. (*Z*)-3-Benzyl-5-benzylidene-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9a**)

Yield: 61% (stepwise from **10a**); beige solid; mp: 127–129 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.76 (bs, 1H), 7.44–7.33 (m, 4H), 7.27–7.12 (m, 6H), 7.03–6.94 (m, 2H), 6.91–6.82 (m, 3H), 4.87 (d, $J = 14.5$ Hz, 1H), 4.49 (dd, $J = 8.8, 7.0$ Hz, 1H), 3.70 (d, $J = 14.5$ Hz, 1H), 1.51–1.21 (m, 2H), 1.10–0.78 (m, 2H), 0.57 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 157.2, 139.3, 137.7, 137.6, 137.2, 129.6, 129.1, 128.94, 128.92, 128.5, 128.3, 128.0, 127.4, 127.2, 125.3, 121.7, 118.6, 54.5, 53.9, 33.7, 19.5, 13.8; IR (ATR, neat): ν 3210, 3066, 3023, 2960, 2926, 2860, 1655, 1576, 1474, 1454, 1432, 1339, 1281, 1260, 1219, 830, 755, 721, 697 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{H}]^+$) for $\text{C}_{26}\text{H}_{27}\text{N}_2\text{O}^+$ calcd. 383.2118, found 383.2116.

4.6.2. (Z)-5-Benzylidene-3-(4-methoxybenzyl)-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9b**)

Yield: 51% (stepwise from **10b**); white solid; mp: 220–222 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.71 (bs, 1H), 7.45–7.32 (m, 4H), 7.26–7.16 (m, 3H), 7.03–6.92 (m, 2H), 6.91–6.74 (m, 3H), 6.68 (d, *J* = 8.5 Hz, 2H), 4.81 (d, *J* = 14.4 Hz, 1H), 4.49 (t, *J* = 7.8 Hz, 1H), 3.77 (s, 1H), 3.64 (d, *J* = 14.4 Hz, 1H), 1.50–1.26 (m, 2H), 1.12–0.82 (m, 2H), 0.59 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.0, 156.7, 139.2, 137.7, 136.9, 130.3, 129.8, 129.7, 129.2, 129.0, 128.6, 128.1, 127.3, 125.3, 121.9, 118.3, 113.7, 55.3, 54.1, 53.1, 33.7, 19.6, 13.9; IR (ATR, neat): ν 3325, 3210, 3071, 3022, 2960, 2926, 2853, 1655, 1614, 1575, 1511, 1474, 1436, 1323, 1305, 1281, 1233, 1305, 1281, 1233, 1220, 1173, 1029, 831, 761, 754, 699, 688, 658 cm⁻¹; HRMS (ESI, [M+Na]⁺) for C₂₇H₂₈N₂O₂Na⁺ calcd. 435.2043, found 435.2055.

4.6.3. (Z)-5-Benzylidene-3-butyl-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9c**)

After column chromatography, product **9c** was additionally purified by washing with diethyl ether. Yield: 62% (stepwise from **10c**), 52% (one-pot from **3c** and **11a**); white solid; mp: 243–245 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.25 (bs, 1H), 7.45–7.35 (m, 3H), 7.34–7.17 (m, 4H), 7.01–6.94 (m, 1H), 6.94–6.87 (m, 2H), 4.57 (t, *J* = 7.9 Hz, 1H), 3.46–3.32 (m, 1H), 3.11–2.97 (m, 1H), 1.75–1.61 (m, 1H), 1.61–1.48 (m, 1H), 1.45–1.20 (m, 3H), 1.20–1.01 (m, 4H), 0.84 (t, *J* = 7.3 Hz, 3H), 0.71 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.1, 139.6, 137.5, 137.1, 129.7, 129.0, 128.9, 128.6, 128.3, 127.3, 125.3, 121.6, 118.2, 55.7, 51.2, 34.3, 30.3, 20.0, 19.9, 14.2, 13.7; IR (ATR, neat): ν 3218, 3116, 3077, 3020, 2958, 2933, 2872, 1656, 1577, 1476, 1462, 1434, 1361, 1302, 1219, 1074, 817, 749, 699, 661 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₂₃H₂₉N₂O calcd. 349.2274, found 349.2256.

4.6.4. (Z)-5-Benzylidene-4-isobutyl-3-(4-methoxybenzyl)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9d**)

After column chromatography, product **9d** was additionally purified by washing with diethyl ether. Yield: 42% (stepwise from **10d**), 40% (one-pot from **3d** and **11a**); white solid; mp: 223–226 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.69 (bs, 1H), 7.48–7.32 (m, 4H), 7.25–7.16 (m, 3H), 7.05–6.90 (m, 3H), 6.84 (d, *J* = 8.4 Hz, 2H), 6.70 (d, *J* = 8.4 Hz, 2H), 4.89 (d, *J* = 14.4 Hz, 1H), 4.52 (t, *J* = 7.0 Hz, 1H), 3.78 (s, 3H), 3.74 (d, *J* = 14.5 Hz, 1H), 1.38–1.19 (m, 3H), 0.58 (d, *J* = 5.8 Hz, 3H), 0.49 (d, *J* = 5.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.0, 157.1, 139.7, 137.7, 137.1, 130.4, 129.8, 129.6, 129.2, 128.9, 128.5, 127.8, 127.2, 125.5, 121.8, 118.5, 113.7, 55.4, 53.1, 52.8, 40.8, 24.9, 22.7, 22.6; IR (ATR, neat): ν 3210, 3071, 3022, 2960, 2902, 1655, 1615, 1576, 1510, 1475, 1435, 1323, 1238, 1218, 1172, 1030, 834, 766, 755, 698, 659 cm⁻¹; HRMS (ESI, [M+Na]⁺) for C₂₈H₃₀N₂O₂Na⁺ calcd. 449.2199, found 449.2197.

4.6.5. (Z)-5-Benzylidene-3-(4-methoxybenzyl)-4-phenyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9e**)

After column chromatography, product **9e** was additionally purified by washing with diethyl ether. Yield: 39% (stepwise from **10e**), 38% (one-pot from **3e** and **11a**); beige solid; mp: 246–248 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.58–7.47 (m, 2H), 7.36–7.28 (m, 3H), 7.26–7.17 (m, 3H), 7.15–7.06 (m, 4H), 7.05–6.99 (m, 2H), 6.98–6.90 (m, 1H), 6.80 (d, *J* = 8.5 Hz, 2H), 6.68–6.58 (m, 3H), 5.87 (s, 1H), 4.70 (d, *J* = 14.4 Hz, 1H), 4.01 (d, *J* = 14.4 Hz, 1H), 3.74 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.1, 157.5, 138.5, 137.4, 137.2, 136.4, 130.6, 129.7, 129.2, 129.0, 128.84, 128.82, 128.80, 128.2, 127.5, 127.0, 126.1, 125.8, 122.0, 118.8, 113.8, 57.53, 55.26, 53.00; IR (ATR, neat): ν 3212, 3077, 3026, 2832, 1661, 1577, 1510, 1472, 1436, 1302, 1237, 1218, 1174, 1028, 824, 766, 750, 737, 698, 655 cm⁻¹; HRMS (ESI, [M+Na]⁺) for C₃₀H₂₆N₂O₂Na⁺ calcd. 469.1886, found 469.1878.

4.6.6. (Z)-4-Benzyl-5-benzylidene-3-(4-methoxybenzyl)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9f**)

After column chromatography, product **9f** was additionally purified by washing with diethyl ether. Yield: 50% (stepwise from **10f**); white solid; mp: 212–214 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.99–7.78 (m, 1H), 7.43–7.36 (m, 1H), 7.33–7.26 (m, 2H), 7.26–7.19 (m, 2H), 7.19–7.11 (m, 3H), 7.10–7.02 (m, 1H), 7.00–6.93 (m, 1H), 6.89 (s, 1H), 6.78–6.68 (m, 4H), 6.61–6.54 (m, 2H), 6.54–6.46 (m, 2H), 4.91 (d, *J* = 14.3 Hz, 1H), 4.55 (dd, *J* = 10.6, 4.4 Hz, 1H), 3.81 (s, 3H), 3.42 (d, *J* = 14.3 Hz, 1H), 2.86 (dd, *J* = 12.8, 10.8 Hz, 1H), 2.44 (dd, *J* = 13.0, 4.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 159.2, 156.7, 138.0, 137.3, 137.0, 130.5, 130.1, 129.6, 129.5, 129.2, 129.0, 128.7, 128.4, 128.3, 127.1, 126.7, 125.2, 122.1, 118.6, 113.8, 55.7, 55.4, 52.7, 38.5; IR (ATR, neat): ν 3219, 3079, 2961, 2923, 2851, 1656, 1606, 1577, 1509, 1462, 1438, 1352, 1297, 1236, 1221, 1176, 1031, 831, 765, 758, 746, 701 cm⁻¹; HRMS (ESI, [M+Na]⁺) for C₃₁H₂₈N₂O₂Na⁺ calcd. 483.2043, found 483.2034.

4.6.7. (Z)-3-Benzyl-5-(4-fluorobenzylidene)-4-isobutyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9g**)

Yield: 53% (stepwise from **10g**), 40% (one-pot from **3g** and **11a**); beige solid; mp: 208–211 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.65 (bs, 1H), 7.38 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.26–7.15 (m, 4H), 7.11–6.96 (m, 5H), 6.96–6.91 (m, 2H), 6.86 (s, 1H), 6.84 (dd, *J* = 8.1, 0.6 Hz, 1H), 4.49–4.40 (m, 1H), 4.44 (t, *J* = 7.3 Hz, 1H), 3.97 (d, *J* = 14.6 Hz, 1H), 1.36–1.21 (m, 3H), 0.56 (d, *J* = 6.1 Hz, 3H), 0.50 (d, *J* = 6.0 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 162.0 (d, *J* = 247.0 Hz), 157, 139.8, 137.6, 137.0, 133.5 (d, *J* = 3.4 Hz), 130.7 (d, *J* = 7.9 Hz), 129.6, 129.1, 128.9, 128.4, 127.6, 127.0, 125.4, 121.9, 118.5 (d, *J* = 1.3 Hz), 115.46 (d, *J* = 21.4 Hz), 54.0, 53.4, 40.9, 24.9, 22.7, 22.6; IR (ATR, neat): ν 3213, 3068, 2952, 2923, 2868, 1657, 1579, 1504, 1473, 1454, 1431, 1329, 1286, 1218, 1155, 832, 757, 745, 730, 700, 657, 618 cm⁻¹; HRMS (ESI, [M+Na]⁺) for C₂₇H₂₇FN₂O₂Na⁺ calcd. 437.2000, found 437.2007.

4.6.8. (Z)-4-((3-Butyl-4-isobutyl-2-oxo-1,2,3,4-tetrahydro-5H-benzo[d][1,3]diazepin-5-ylidene)methyl)benzonitrile (**9h**)

Yield: 62% (stepwise from **10h**), 47% (one-pot from **3i** and **11a**); beige solid; mp: 236–238 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.54 (bs, 1H), 7.71 (d, *J* = 7.9 Hz, 2H), 7.42–7.32 (m, 3H), 7.29–7.20 (m, 1H), 7.04–6.91 (m, 2H), 6.86 (s, 1H), 4.50 (t, *J* = 7.3 Hz, 1H), 3.52–3.37 (m, 1H), 3.11–2.97 (m, 1H), 1.72–1.50 (m, 2H), 1.44–1.31 (m, 1H), 1.23–1.04 (m, 4H), 0.91–0.79 (m, 6H), 0.75 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 156.0, 142.4, 142.2, 137.2, 132.4, 129.7, 129.61, 129.55, 125.7, 124.6, 121.8, 118.7, 118.5, 111.0, 54.4, 51.5, 41.2, 30.4, 25.1, 23.1, 22.9, 20.0, 13.8; IR (ATR, neat): ν 3198, 3056, 2955, 2933, 2866, 2223, 1653, 1603, 1580, 1500, 1486, 1474, 1436, 1362, 1339, 1308, 1228, 876, 832, 781, 746, 662 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₂₅H₃₀N₃O calcd. 388.2383, found 388.2364.

4.6.9. (Z)-3-Benzyl-4-isobutyl-5-(4-(trifluoromethyl)benzylidene)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**9i**)

After column chromatography, product **9i** was additionally purified by washing with diethyl ether. Yield: 50% (stepwise from **10i**); white solid; mp: 232–235 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.76–7.51 (m, 3H), 7.44–7.36 (m, 1H), 7.31–7.09 (m, 6H), 7.05–6.97 (m, 1H), 6.90 (s, 1H), 6.89–6.77 (m, 3H), 4.71 (d, *J* = 14.7 Hz, 1H), 4.42 (t, *J* = 7.3 Hz, 1H), 3.97 (d, *J* = 14.7 Hz, 1H), 1.48–1.22 (m, 3H), 0.60 (d, *J* = 6.2 Hz, 3H), 0.51 (d, *J* = 6.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 157.0, 141.2, 141.0, 137.2, 137.1, 129.7, 129.5, 129.3 (q, *J* = 32.5 Hz), 128.8, 128.5, 127.7, 126.3, 125.5 (q, *J* = 3.7 Hz), 125.0, 124.3 (q, *J* = 271.9 Hz), 122.0, 118.6, 53.9, 53.1, 40.8, 25.0, 22.8, 22.6; IR (ATR, neat): ν 3327, 3205, 3112, 3068, 2966, 2957, 2936, 2902, 2872, 1655, 1580, 1508, 1472, 1456, 1436, 1361, 1321, 1226, 1160, 1107, 1067, 1017, 884, 875, 831, 818, 751, 731, 701, 668 cm⁻¹; HRMS (ESI, [M+Na]⁺) for C₂₈H₂₇F₃N₂O₂Na⁺ calcd.

487.1968, found 487.1959.

4.6.10. (Z)-3-(4-Methoxybenzyl)-4-propyl-5-(thiophen-3-ylmethylene)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9j)

Yield: 36% (stepwise from **10j**); beige solid; mp: 206–208 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.53 (bs, 1H), 7.41–7.32 (m, 2H), 7.26–7.18 (m, 1H), 7.03–6.89 (m, 5H), 6.83–6.79 (m, 1H), 6.78 (s, 1H), 6.74 (d, $J = 8.5$ Hz, 2H), 4.76 (d, $J = 14.5$ Hz, 1H), 4.61 (dd, $J = 8.7, 7.0$ Hz, 1H), 3.87 (d, $J = 14.5$ Hz, 1H), 3.79 (s, 3H), 1.51–1.32 (m, 2H), 1.13–0.84 (m, 2H), 0.62 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 159.0, 157.0, 139.2, 138.2, 136.9, 130.1, 129.8, 129.6, 128.97, 128.95, 125.8, 125.3, 123.2, 122.4, 121.9, 118.5, 113.8, 55.3, 54.7, 53.4, 33.7, 19.6, 13.9; IR (ATR, neat): ν 3322, 3220, 3114, 3079, 2990, 2968, 2936, 1656, 1606, 1577, 1509, 1462, 1437, 1352, 1297, 1236, 1221, 1176, 1031, 831, 765, 758, 746, 702 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{Na}]^+$) for $\text{C}_{25}\text{H}_{26}\text{N}_2\text{O}_2\text{SNa}^+$ calcd. 441.1607, found 441.1597.

4.6.11. (Z)-3-(4-Methoxybenzyl)-5-pentylidene-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9k)

The isolated product was contaminated with unidentified impurities. Yield: 53% (67% purity, stepwise from **10k**); washing with diethyl ether can improve the purity but leads to significant losses of **9k**; yield after wash: 32% (78% purity); white solid; mp: 185–188 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.75 (bs, 1H), 7.30 (d, $J = 8.5$ Hz, 2H), 7.20–7.10 (m, 2H), 6.94–6.82 (m, 3H), 6.81–6.75 (m, 1H), 5.68 (t, $J = 7.3$ Hz, 1H), 4.89 (d, $J = 14.8$ Hz, 1H), 4.48 (d, $J = 14.8$ Hz, 1H), 4.24 (dd, $J = 8.9, 6.8$ Hz, 1H), 3.80 (s, 3H), 1.91–1.77 (m, 1H), 1.70–1.59 (m, 1H), 1.47–1.36 (m, 2H), 1.29–1.17 (m, 4H), 1.06–0.92 (m, 2H), 0.90–0.83 (m, 3H), 0.68 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 159.2, 156.1, 136.6, 136.1, 131.5, 130.2, 129.8, 129.4, 128.3, 126.6, 121.9, 117.8, 114.1, 55.4, 54.6, 53.3, 34.0, 32.1, 27.8, 22.6, 19.4, 14.1, 13.7; IR (ATR, neat): ν 3198, 3058, 2962, 2932, 2861, 1653, 1581, 1512, 1461, 1434, 1336, 1249, 1226, 1176, 1036, 853, 830, 760, 732, 689 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{Na}]^+$) for $\text{C}_{25}\text{H}_{32}\text{N}_2\text{O}_2\text{Na}^+$ calcd. 415.2356, found 415.2348.

4.6.12. (Z)-5-Butylidene-3-(4-methoxybenzyl)-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9l)

The isolated product was contaminated with unidentified impurities. Yield: 46% (60% purity, stepwise from **10l**); washing with diethyl ether can improve the purity but leads to significant losses of **9l**; yield after wash: 25% (78% purity); beige solid; mp: 163–165 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.16 (bs, 1H), 7.32 (d, $J = 8.4$ Hz, 2H), 7.21–7.10 (m, 2H), 6.94–6.81 (m, 4H), 5.68 (t, $J = 7.2$ Hz, 1H), 4.91 (d, $J = 14.8$ Hz, 1H), 4.50 (d, $J = 14.8$ Hz, 1H), 4.24 (dd, $J = 9.1, 6.5$ Hz, 1H), 3.80 (s, 3H), 1.87–1.75 (m, 1H), 1.70–1.58 (m, 1H), 1.47–1.36 (m, 2H), 1.36–1.23 (m, 2H), 1.05–0.94 (m, 2H), 0.84 (t, $J = 7.3$ Hz, 3H), 0.68 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 159.2, 156.3, 136.8, 136.4, 131.2, 130.3, 129.9, 129.2, 128.3, 126.6, 121.7, 118.0, 114.1, 55.4, 54.6, 53.3, 34.0, 30.1, 23.1, 19.3, 14.0, 13.7; IR (ATR, neat): ν 3200, 3062, 2957, 2930, 2859, 1654, 1613, 1581, 1512, 1487, 1462, 1435, 1334, 1309, 1248, 1228, 1175, 1037, 853, 828, 762, 734, 689 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{Na}]^+$) for $\text{C}_{24}\text{H}_{30}\text{N}_2\text{O}_2\text{Na}^+$ calcd. 401.2199, found 401.2201.

4.6.13. (Z)-3-Butyl-5-(4-fluorobenzylidene)-4-isobutyl-7,9-dimethyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9m)

Yield: 64% (stepwise from **10m**), 48% (one-pot from **3h** and **11b**); beige solid; mp: 168–170 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.24–7.15 (m, 2H), 7.13–7.04 (m, 2H), 7.02 (s, 1H), 6.96 (s, 1H), 6.80 (s, 1H), 6.63 (bs, 1H), 4.50 (t, $J = 7.2$ Hz, 1H), 3.48–3.33 (m, 1H), 3.09–2.96 (m, 1H), 2.29 (s, 3H), 2.27 (s, 3H), 1.61–1.47 (m, 2H), 1.38–1.02 (m, 5H), 0.86–0.78 (m, 6H), 0.73 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 162.0 (d, $J = 247.2$ Hz), 155.3, 140.6, 133.5

(d, $J = 3.5$ Hz), 132.7, 131.7, 130.6, 130.5 (d, $J = 7.9$ Hz), 128.4, 127.3, 125.7, 123.3, 115.5 (d, $J = 21.5$ Hz), 54.4, 51.4, 41.7, 30.4, 25.0, 22.91, 22.90, 20.5, 20.0, 18.5, 13.7; IR (ATR, neat): ν 3225, 2959, 2927, 2870, 1641, 1505, 1465, 1430, 1317, 1220, 863, 836, 821, 781, 744, 612 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{Na}]^+$) for $\text{C}_{26}\text{H}_{33}\text{FN}_2\text{ONa}^+$ calcd. 431.2469, found 431.2473.

4.6.14. (Z)-3-Benzyl-4-isobutyl-7,9-dimethyl-5-(4-(trifluoromethyl)benzylidene)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9n)

Yield: 69% (stepwise from **10n**); beige solid; mp: 147–148 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.56 (d, $J = 8.1$ Hz, 2H), 7.23–7.10 (m, 5H), 7.06 (s, 1H), 7.01 (s, 1H), 6.91–6.83 (m, 3H), 6.78 (s, 1H), 4.67 (d, $J = 14.6$ Hz, 1H), 4.41 (t, $J = 7.2$ Hz, 1H), 4.07 (d, $J = 14.6$ Hz, 1H), 2.35 (s, 3H), 2.30 (s, 3H), 1.42–1.19 (m, 3H), 0.60 (d, $J = 6.1$ Hz, 3H), 0.54 (d, $J = 6.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 156.2, 141.3, 141.2, 137.2, 132.7, 132.1, 131.0, 129.3, 129.2 (d, $J = 32.6$ Hz), 128.8, 128.5, 128.4, 127.6, 126.9, 125.5, 125.4 (q, $J = 3.7$ Hz), 124.3 (d, $J = 272.0$ Hz), 123.7, 53.7, 53.2, 41.0, 24.9, 22.6, 22.6, 20.5, 18.5; IR (ATR, neat): ν 3306, 3240, 2959, 2926, 2869, 1637, 1455, 1322, 1292, 1163, 1125, 1103, 1066, 1017, 907, 862, 841, 760, 734, 714, 700 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{Na}]^+$) for $\text{C}_{30}\text{H}_{31}\text{F}_3\text{N}_2\text{ONa}^+$ calcd. 515.2281, found 515.2280.

4.6.15. (Z)-5-Benzylidene-3-butyl-7,8-dimethoxy-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9o)

Yield: 64% (stepwise from **10o**); brown solid; mp: 183–184 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.76 (bs, 1H), 7.46–7.38 (m, 2H), 7.34–7.24 (m, 3H), 6.90 (s, 2H), 6.83 (s, 1H), 4.52 (t, $J = 7.8$ Hz, 1H), 3.75 (s, 3H), 3.72 (s, 3H), 3.35–3.24 (m, 1H), 2.85–2.74 (m, 1H), 1.72–1.58 (m, 1H), 1.57–1.43 (m, 1H), 1.41–1.17 (m, 2H), 1.02–0.87 (m, 4H), 0.82 (t, $J = 7.3$ Hz, 3H), 0.61 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 155.2, 149.4, 143.5, 138.5, 137.4, 131.2, 128.7, 128.4, 126.9, 125.3, 115.8, 112.0, 102.3, 55.8, 55.3, 54.4, 49.8, 33.5, 29.6, 19.27, 19.25, 14.0, 13.4; IR (ATR, neat): ν 3342, 3212, 3090, 2950, 2929, 2857, 1664, 1444, 1251, 861, 697 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{H}]^+$) for $\text{C}_{25}\text{H}_{33}\text{N}_2\text{O}_3$ calcd. 409.2486, found 409.2478.

4.6.16. (Z)-5-Benzylidene-3-butyl-7-fluoro-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (9p)

Yield: 57% (stepwise from **10p**); beige solid; mp: 187–188 °C; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 9.08 (s, 1H), 7.48–7.40 (m, 2H), 7.37–7.27 (m, 3H), 7.23 (dd, $J = 10.1, 2.7$ Hz, 1H), 7.18–7.04 (m, 2H), 6.99 (s, 1H), 4.52 (t, $J = 7.8$ Hz, 1H), 3.33–3.21 (m, 1H), 2.92–2.79 (m, 1H), 1.69–1.53 (m, 1H), 1.53–1.39 (m, 1H), 1.38–1.12 (m, 2H), 1.04–0.86 (m, 4H), 0.79 (t, $J = 7.3$ Hz, 3H), 0.61 (t, $J = 6.9$ Hz, 3H); ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ 156.7 (d, $J = 237.0$ Hz), 154.7, 137.9 (d, $J = 1.4$ Hz), 136.8, 134.0 (d, $J = 1.9$ Hz), 128.7, 128.5, 127.3, 125.8 (d, $J = 7.3$ Hz), 119.5 (d, $J = 8.1$ Hz), 115.8 (d, $J = 22.7$ Hz), 114.8 (d, $J = 22.9$ Hz), 54.2, 49.8, 33.5, 29.6, 19.3, 19.2, 13.9, 13.4; IR (ATR, neat): ν 3334, 3221, 3102, 3065, 2957, 2931, 2872, 1660, 1475, 1222, 1189, 862, 828, 763, 700 cm^{-1} ; HRMS (ESI, $[\text{M}+\text{H}]^+$) for $\text{C}_{23}\text{H}_{28}\text{FN}_2\text{O}^+$ calcd. 367.2180, found 367.2167.

4.7. General procedure for the synthesis of 1,3-benzodiazepines 19 by base-promoted alkylation of 9

1,3-Benzodiazepine **9** (0.3 mmol) was placed in a screw cap vial followed by addition of dry THF (1 mL), sodium hydride (19.2 mg, 60% dispersion in mineral oil, 0.48 mmol) and benzyl chloride **17** (0.6 mmol) or methyl iodide (**18**, 85 mg, 0.6 mmol). The resulting mixture was sealed and stirred at 60 °C for 3 h. Upon completion of this time, the mixture was diluted with ethyl acetate and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on silica gel using petroleum ether-ethyl acetate

(9:1 → 8:2) mixture as eluent provided pure 1,3-benzodiazepine **19**.

4.7.1. (Z)-1-Benzyl-5-benzylidene-4-isobutyl-3-(4-methoxybenzyl)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**19a**)

Yield: 93%; white solid; mp: 141–143 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.34–7.26 (m, 3H), 7.26–7.08 (m, 11H), 7.00–6.94 (m, 2H), 6.79 (d, *J* = 8.6 Hz, 2H), 6.70 (s, 1H), 5.18 (d, *J* = 15.4 Hz, 1H), 4.96 (d, *J* = 15.4 Hz, 1H), 4.60–4.49 (m, 2H), 4.27 (d, *J* = 14.6 Hz, 1H), 3.82 (s, 3H), 1.65–1.54 (m, 1H), 1.43–1.30 (m, 1H), 1.18–1.06 (m, 1H), 0.59 (d, *J* = 6.6 Hz, 3H), 0.42 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.3, 159.0, 141.7, 139.2, 138.8, 136.7, 134.7, 130.5, 130.3, 130.1, 128.6, 128.6, 128.5, 128.3, 127.7, 127.1, 126.8, 124.5, 121.7, 113.9, 58.6, 55.4, 55.1, 51.7, 42.1, 24.6, 23.1, 22.0; IR (ATR, neat): ν 3029, 2954, 2931, 2865, 1615, 1509, 1454, 1413, 1242, 1200, 1174, 1031, 770, 759, 700, 692 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₃₅H₃₇N₂O₂ calcd. 517.2850, found 517.2860.

4.7.2. (Z)-5-Benzylidene-3-(4-methoxybenzyl)-1-methyl-4-phenyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**19b**)

Yield: 84%; white solid; mp: 144–147 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.30–7.17 (m, 5H), 7.13–7.05 (m, 5H), 7.05–6.94 (m, 5H), 6.85–6.78 (m, 2H), 6.74 (d, *J* = 8.6 Hz, 2H), 5.71 (s, 1H), 4.28 (d, *J* = 14.3 Hz, 1H), 4.17 (d, *J* = 14.3 Hz, 1H), 3.79 (s, 3H), 3.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.6, 159.1, 141.6, 140.0, 136.7, 136.6, 131.0, 130.8, 129.4, 128.84, 128.75, 128.6, 128.4, 128.2, 127.3, 127.0, 125.8, 123.4, 119.8, 113.8, 61.2, 55.3, 51.0, 37.8; IR (ATR, neat): ν 2954, 2922, 2853, 1649, 1607, 1508, 1493, 1458, 1446, 1299, 1258, 1235, 1172, 1098, 1033, 851, 765, 749, 737, 725, 703, 609 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₃₁H₂₉N₂O₂ calcd. 461.2224, found 461.2231.

4.7.3. (Z)-5-Benzylidene-3-butyl-1-methyl-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**19c**)

Yield: 89%; yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ 7.51 (dd, *J* = 7.7, 1.3 Hz, 1H), 7.43–7.35 (m, 2H), 7.35–7.25 (m, 4H), 7.15–7.03 (m, 2H), 6.92 (s, 1H), 4.49 (t, *J* = 7.6 Hz, 1H), 3.31 (s, 3H), 3.20–3.07 (m, 2H), 1.88–1.73 (m, 1H), 1.47–1.18 (m, 5H), 1.18–1.04 (m, 2H), 0.79 (t, *J* = 7.2 Hz, 3H), 0.76 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 159.2, 141.5, 139.3, 137.4, 130.4, 128.8, 128.7, 128.52, 128.45, 127.9, 127.2, 122.9, 119.1, 58.9, 50.4, 38.0, 34.9, 30.2, 20.1, 19.5, 14.0, 13.8; IR (ATR, neat): ν 2957, 2928, 2871, 1649, 1596, 1459, 1447, 1300, 1233, 1118, 1096, 1033, 753, 700 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₂₄H₃₁N₂O⁺ calcd. 363.2431, found 363.2443.

4.7.4. (Z)-5-Benzylidene-3-butyl-1-(3-chlorobenzyl)-4-propyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**19d**)

Yield: 95%; yellowish oil; ¹H NMR (400 MHz, CDCl₃): δ 7.42–7.33 (m, 2H), 7.33–7.19 (m, 6H), 7.17–7.03 (m, 5H), 6.78 (s, 1H), 5.11 (d, *J* = 15.6 Hz, 1H), 4.91 (d, *J* = 15.6 Hz, 1H), 4.41 (dd, *J* = 8.6, 5.2 Hz, 1H), 3.34–3.20 (m, 1H), 3.19–3.05 (m, 1H), 1.71–1.56 (m, 1H), 1.52–1.35 (m, 2H), 1.25–0.94 (m, 5H), 0.81 (t, *J* = 7.3 Hz, 3H), 0.68 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 158.1, 141.5, 141.2, 139.2, 136.7, 134.6, 134.2, 130.7, 129.6, 128.8, 128.61, 128.59, 128.4, 127.46, 127.45, 126.9, 125.6, 124.5, 121.4, 62.1, 54.7, 50.4, 35.8, 30.5, 20.3, 19.0, 14.0, 13.9; IR (ATR, neat): ν 2957, 2930, 2871, 1626, 1596, 1576, 1455, 1355, 1286, 1241, 1210, 1077, 760, 699, 683 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₃₀H₃₄ClN₂O⁺ calcd. 473.2354, found 473.2362.

4.7.5. (Z)-3-Butyl-5-(4-fluorobenzylidene)-4-isobutyl-1,7,9-trimethyl-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**19e**)

Yield: 96%; white solid; mp: 131–133 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.26–7.19 (m, 2H), 7.08–6.96 (m, 3H), 6.85 (s, 1H), 6.73 (s, 1H), 4.21 (dd, *J* = 10.9, 2.5 Hz, 1H), 3.54–3.39 (m, 1H), 3.12 (s, 3H), 2.87–2.70 (m, 1H), 2.33 (s, 3H), 2.25 (s, 3H), 1.59–1.42 (m, 2H),

1.40–1.04 (m, 4H), 0.98–0.82 (m, 4H), 0.69 (d, *J* = 6.7 Hz, 3H), 0.39 (d, *J* = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 162.1 (d, *J* = 246.9 Hz), 161.0, 139.4, 138.8, 136.8, 135.7, 132.6, 132.5 (d, *J* = 3.4 Hz), 131.5, 130.5 (d, *J* = 8.0 Hz), 129.4, 125.5115.51 (d, *J* = 21.4 Hz), 63.0, 48.1, 42.0, 38.8, 30.8, 24.4, 24.0, 21.1, 20.9, 20.6, 18.6, 14.0; IR (ATR, neat): ν 2957, 2925, 2858, 1642, 1626, 1603, 1507, 1466, 1459, 1447, 1367, 1343, 1279, 1220, 1157, 1146, 1078, 858, 830, 817, 787, 759 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₂₇H₃₆N₂O⁺ calcd. 423.2806, found 423.2819.

4.8. General procedure for PMB-deprotection of 1,3-benzodiazepines **9f,e**²³

1,3-Benzodiazepine **9f** (92 mg, 0.2 mmol) was placed in a screw cap vial followed by addition of DCM (1.5 mL), trifluoroacetic acid (0.5 mL) and triflic acid (12 μL). The resulting mixture was sealed and stirred at 50 °C for 3 h. Upon completion of this time, the mixture was diluted with ethyl acetate and transferred to the round bottom flask. Then the silicagel was added and the mixture was concentrated under reduced pressure. Column chromatography on silica gel using petroleum ether-ethyl acetate (1:1) mixture as eluent provided 1,3-benzodiazepine **20**. Starting from **9e** (45 mg, 0.1 mmol), 1,3-benzodiazepine **21** was obtained following the same procedure and using petroleum ether-ethyl acetate (9:1 → 8:2) mixture as eluent for column chromatography.

4.8.1. (Z)-4-Benzyl-5-benzylidene-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one (**20**)

Yield: 90%; white solid; mp: 154–155 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 9.10 (bd, *J* = 1.5 Hz, 1H), 7.58 (dd, *J* = 7.2, 1.7 Hz, 1H), 7.37–7.14 (m, 9H), 7.14–7.08 (m, 2H), 7.02–6.94 (m, 1H), 6.93–6.85 (m, 2H), 6.73 (m, 1H), 4.52 (q, *J* = 7.4 Hz, 1H), 2.76 (dd, *J* = 13.4, 7.3 Hz, 1H), 2.64 (dd, *J* = 13.4, 7.8 Hz, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 155.4, 139.4, 137.9, 137.4, 136.6, 129.8, 129.0, 128.8, 128.6, 128.3, 128.2, 127.8, 127.1, 126.3, 126.2, 121.3, 118.1, 50.0, 40.3; IR (ATR, neat): ν 3215, 3027, 1683, 1480, 1421, 1231, 746, 697 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₂₃H₂₁N₂O⁺ calcd. 341.1648, found 341.1638.

4.8.2. 5-Benzyl-4-phenyl-1,3-dihydro-2H-benzo[d][1,3]diazepin-2-one (**21**)

Yield: 43%; beige solid; mp: 179–180 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 7.79–7.73 (m, 1H), 7.68 (bs, 1H), 7.52–7.36 (m, 7H), 7.29–7.17 (m, 3H), 7.16–7.06 (m, 4H), 4.06–4.00 (m, 2H), ¹³C NMR (100 MHz, DMSO-d₆): δ 152.5, 140.7, 135.92, 135.85, 131.9, 129.2, 128.32, 128.28, 128.24, 128.0, 127.9, 125.9, 123.3, 121.1, 119.3, 115.5, 112.6, 29.6; IR (ATR, neat): ν 3464, 3291, 3178, 2921, 1678, 1604, 1452, 1388, 1338, 740, 698 cm⁻¹; HRMS (ESI, [M+H]⁺) for C₂₂H₁₉N₂O⁺ calcd. 327.1492, found 327.1479.

Acknowledgements

This work was supported by the startup fund from Soochow University (grant Q410900714), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and the project of scientific and technologic infrastructure of Suzhou (grant SZS201708). K.V.H. thanks the Hercules Foundation (project AUG/11/029 '3D-SPACE: 3D Structural Platform Aiming for Chemical Excellence') and the Research Foundation - Flanders (FWO) for funding. E.V.V.d.E. acknowledges the financial support from The Ministry of Education and Science of the Russian Federation (the Agreement number 02.a03.0008). The authors are also grateful to the undergraduate students of intensive training class of Soochow University, China for their participation in the approbation of the described methodology.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.tet.2017.09.034>.

References

- For an overview of chemistry and biology of 3-benzazepines, see: a) Kametani T, Fukumoto K. *Heterocycles*. 1975;3:931–1004; b) Weinstock J, Hieble JP, Wilson JW. *Drugs Future*. 1985;10:645–696; c) Kawase M, Saito S, Motohashi N. *Int J Antimicrob Agents*. 2000;14:193–201; d) Donets P. A., PhD Dissertation, University of Leuven (KU Leuven), Belgium, 2011; e) Peshkov V. A., PhD Dissertation, University of Leuven (KU Leuven), Belgium, 2013; f) Petuškovs A, Shubin K. *Chem Heterocycl Comp*. 2016;52:84–86.
- For an overview of chemistry and biology of 1,4-benzodiazepines, see: a) Archer GA, Sternbach LH. *Chem Rev*. 1968;68:747–784; b) Sternbach LH. *Angew Chem Int Ed Engl*. 1971;10:34–43; c) Schütz H. *Benzodiazepines. A Handbook. Basic Data, Analytical Methods, Pharmacokinetics and Comprehensive Literature*. Springer-Verlag Berlin Heidelberg; 1982; d) Valdés C, Bayod M. In: Alvarez-Builla J, Vaquero JJ, Barluenga J, eds. *Modern Heterocyclic Chemistry*. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2011:2175–2230; e) Kumar SS, Kavitha HP, Arulmurugan S, Venkatraman BR. *Mini Rev Org Chem*. 2012;9:285–302; f) MacQuarrie S. L., PhD Dissertation, Virginia Polytechnic Institute and State University, Virginia, 2005.
- For a summary on the concept of privileged structures, see: Welsch ME, Snyder SA, Stockwell BR. *Curr Opin Chem Biol*. 2010;14:347–361.
- Murphy MB, Murray C, Shorten GD. *N Engl J Med*. 2001;345:1548–1557.
- a) Bostwick JR, Casher MI, Yasugi S. *Curr Psychiatry*. 2012;11:54–64; b) Mehdi T. *Br J Med Pract*. 2012;5:a501; c) Donoghue J, Lader M. *Int J Psychiatry Clin Pract*. 2010;14:78–87.
- a) D'Souza AM, Spiccia N, Basutto J, et al. *Org Lett*. 2011;13:486–489.
- a) Geyer III HM, Martin LL, Crichlow CA, et al. *J Med Chem*. 1982;25:340–346; b) Martin LL, Setescak LL, Worm M, Crichlow C, Geyer III HM, Wilker JC. *J Med Chem*. 1982;25:346–351; c) Miki T, Kori M, Fujishima A, et al. *Bioorg Med Chem*. 2002;10:385–400; d) Bayssat M., Ferrand G., Depin J. C., (LIPHA), US4554273 (A), 1985; e) Rodgers J. D., Cocuzza A. J., Bilder D. M., (DuPont Pharmaceutical Company), US6204262, 2001;
- For reviews on A³-coupling, see: a) Yoo W-J, Zhao L, Li C-J. *Aldrichim Acta*. 2011;44:43–51; b) Zani L, Bolm C. *Chem Commun*. 2006:4263–4275; c) Li C-J. *Acc Chem Res*. 2010;43:581–590; d) Kouznetsov VV, Vargas Méndez LY. *Synthesis*. 2008:491–506; e) Peshkov VA, Pereshivko OP, Van der Eycken EV. *Chem Soc Rev*. 2012;41:3790–3807; f) Seidel D. *Org Chem Front*. 2014;1:426–429.
- For the recent examples, see: a) Paioti PHS, Abboud KA, Aponick A. *ACS Catal*. 2017;7:2133–2138; b) Nechaev AA, Peshkov AA, Peshkov VA, Van der Eycken EV. *Eur J Org Chem*. 2017:1063–1069; c) Ajay S, Saidharedy P, Shaw AK. *Asian J Org Chem*. 2017;6:503–506; d) Li J, Rudolph M, Rominger F, Xie J, Hashmi ASK. *Adv Synth Catal*. 2016;358:207–211; e) Fedoseev P, Sharma N, Khunt R, Ermolat'ev DS, Van der Eycken EV. *RSC Adv*. 2016;6:75202–75206; f) Van Beek WE, Van Stappen J, Franck P, Tehrani KA. *Org Lett*. 2016;18:4782–4785; g) Rajesh UC, Gulati U, Rawat DS. *ACS Sustainable Chem Eng*. 2016;4:3409–3419; h) Afraj SN, Nuzlia C, Chen C, Lee G-H. *Asian J Org Chem*. 2016;5:1015–1026; i) Selvaraju M, Ye T-Y, Li C-H, Hoa P-H, Sun C-M. *Chem Commun*. 2016;52:6621–6624; j) Choi J, Lim J, Irudayanathan FM, et al. *Asian J Org Chem*. 2016;5:770–777; k) Afraj SN, Chen C. *Asian J Org Chem*. 2016;5:257–263; l) Senthilkumar S, Prasad SS, Das A, Baskaran S. *Chem Eur J*. 2015;21:15914–15918; m) Hooyberghs G, Van Hove S, Jacobs J, Van Meervelt L, Van der Eycken EV. *Eur J Org Chem*. 2015:4726–4731; n) Fan W, Ma S. *Eur J Org Chem*. 2015:3531–3539; o) Feng H, Jia H, Sun Z. *Adv Synth Catal*. 2015;357:2447–2452.
- Peshkov VA, Pereshivko OP, Donets PA, Mehta VP, Van der Eycken EV. *Eur J Org Chem*. 2010:4861–4867.
- For the cooperative use of redox-A³-coupling and Pd-catalyzed alkyne hydroarylation for the synthesis of protoberberine and aporphine alkaloids, see: Zhou S, Tong R. *Chem Eur J*. 2016;22:7084–7089.
- Peshkov VA, Pereshivko OP, Sharma S, et al. *J Org Chem*. 2011;76:5867–5872.
- For the base-promoted approach towards imidazol-2-ones 5 and related imidazol-2-thiones, see: Ranjan A, Yerande R, Wakchaure PB, Yerande SG, Dethe DH. *Org Lett*. 2014;16:5788–5791.
- Pereshivko OP, Peshkov VA, Jacobs J, Van Meervelt L, Van der Eycken EV. *Adv Synth Cat*. 2013;355:781–789.
- For the enantioselective version, see: Campbell MJ, Toste FD. *Chem Sci*. 2011;2:1369–1378.
- Pereshivko OP, Peshkov VA, Peshkov AA, Jacobs J, Van Meervelt L, Van der Eycken EV. *Org Biomol Chem*. 2014;12:1741–1750.
- For the recent processes involving triple bond carbopalladation to assemble medium-rings, see: a) Tao L, Pan X, Ji M, Chen X, Liu Z. *Tetrahedron*. 2017;73:2159–2171; b) Ghosh T. *New J Chem*. 2017;41:2927–2933; c) Peshkov AA, Peshkov VA, Pereshivko OP, Van Hecke K, Kumar R, Van der Eycken EV. *J Org Chem*. 2015;80:6598–6608; d) Peshkov AA, Peshkov VA, Pereshivko OP, Van der Eycken EV. *Tetrahedron*. 2015;71:3863–3871; e) Mondal S, Debnath S, Das B. *Tetrahedron*. 2015;71:476–486.
- For the synthesis of secondary propargylamines through the A³-coupling, see: a) Bariwal JB, Ermolat'ev DS, Van der Eycken EV. *Chem Eur J*. 2010;16:3281–3284; b) Lu Y, Johnstone TC, Arndtsen BA. *J Am Chem Soc*. 2009;131:11284–11285; c) Hu J, Ma J, Zhang Z, et al. *Green Chem*. 2015;17:1219–1225.
- For the intermolecular alkyne hydroarylation processes under nickel catalysis, see: a) Robbins DW, Hartwig JF. *Science*. 2011;333:1423–1427; b) Dorn SCM, Olsen AK, Kelemen RE, Shrestha R, Weix DJ. *Tetrahedron Lett*. 2015;56:3365–3367.
- CCDC 1558356 (9d) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via: www.ccdc.cam.ac.uk/data_request/cif.
- For the guiding references on such protocols, see: a) Lehmann F, Pettersen A, Currier EA, et al. *J Med Chem*. 2006;49:2232–2240; b) Zhang M, Yang X-Y, Tang W, et al. *ACS Med Chem Lett*. 2012;3:317–321; c) Sanphanya K, Wattanapitayakul SK, Prangsaengtong O, et al. *Bioorg Med Chem Lett*. 2012;22:3001–3005.
- See supporting information for further details.
- Donets PA, Van der Eycken EV. *Org Lett*. 2007;9:3017–3020.